Handelsbanken Fonder Ab Denali Therapeutics Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 39,500 shares of DNLI stock, worth $955,110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,500
Previous 39,500
-0.0%
Holding current value
$955,110
Previous $917,000
25.52%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$323 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$319 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$270 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$259 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$191 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.24B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...